68Ga-FAPI PET/MR for Intracranial and Carotid Atherosclerosis
试验速览
- 阶段
- 早期 1 期
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Diagnostic performance
研究概览
简要总结
A thin-cap fibroatheroma with a large necrotic core and macrophage infiltration marks the vulnerable plaque. Fibroblast activating protein (FAP) is an active serine protease, which can degrade type I collagen, potentially thinning the fibrous cap. Thus we speculate that atherosclerotic plaque could be imaged with 68Ga-FAPI PET/MR.
详细描述
A thin-cap fibroatheroma with a large necrotic core and macrophage infiltration marks the vulnerable plaque. Fibroblast activating protein (FAP) is an active serine protease, which can degrade type I collagen, potentially thinning the fibrous cap. Previous ex vivo analysis of human aortic atheromata revealed that FAP was expressed in atherosclerotic plaques, and higher FAP expression was detected in thin fibrous caps than thick caps. Constitutive Fap deletion in atherosclerosis-prone mice models could reduce plaque formation and improve plaque stability with increased fibrous cap thickness. Thus we speculate that atherosclerotic plaque could be imaged with 68Ga-FAPI PET/MR.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •intracranial or carotid atherosclerosis patients
- •signed informed consent
排除标准
- •pregnancy, breastfeeding
- •contradictions of MRI
- •unstable vital signs
研究组 & 干预措施
68Ga-FAPI, PET/MR
inject 68Ga-FAPI，and then perform PET/MR
干预措施: 68Ga-FAPI (Drug)
结局指标
主要结局
Diagnostic performance
时间窗: through study completion, an average of 2 years
Diagnostic performance of 68Ga-FAPI PET/MR for intracranial or carotid atherosclerosis
次要结局
- SUVmax(through study completion, an average of 2 years)
- FAPI expression(through study completion, an average of 2 years)